Icosapent Ethyl for Primary Versus Secondary Prevention of Major Adverse Cardiovascular Events in Hypertriglyceridemia: Value for Money Analysis

被引:6
作者
Arbel, Ronen [1 ]
Aboalhasan, Enis [1 ]
Hammerman, Ariel [2 ]
Azuri, Joseph [3 ,4 ]
机构
[1] Sapir Coll, Maximizing Hlth Outcomes Res Lab, Sderot, Israel
[2] Clalit Hlth Serv Headquarters, Dept Pharmaceut Technol Assessment, Tel Aviv, Israel
[3] Maccabi Healthcare Serv, Diabet Clin, Tel Aviv, Israel
[4] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
关键词
Hypertriglyceridemia; Icosapent ethyl; Major adverse cardiovascular events; Outcomes research; COST-EFFECTIVENESS; TREAT;
D O I
10.1016/j.amjmed.2020.12.023
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Icosapent ethyl (IPE) is approved for the prevention of major adverse cardiovascular events (MACE) in patients with hypertriglyceridemia. However, due to budget constraints, access to IPE will inevitably be limited to a fraction of eligible patients. To help maximize value for money spent, we estimated the number of preventable MACE when providing IPE for primary versus secondary prevention. METHODS: The number of preventable MACE was estimated by dividing the available budget by the cost needed to treat (CNT) to prevent one MACE. CNT was calculated as the product of the number needed to treat (NNT) to prevent 1 MACE by therapy cost. NNT values were determined according to the Reduction of Cardiovascular Events with Icosapent Ethyl- Intervention Trial (REDUCE-IT) results. The budget limit was set as the United States' threshold suggested by the Institute for Clinical and Economic Review. Sensitivity analysis was performed regarding the cost of IPE in the United States. RESULTS: The NNT to prevent 1 MACE over 4.9 years in the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial primary prevention cohort was 59 (95% confidence interval [CI]: 24-infinity) versus 14 (11-21) for secondary prevention. At an annual IPE cost of $2915, the CNT to prevent 1 MACE was $842,726 (95% CI: $342,804-infinity) and $199,969 ($157,118-$299,953) accordingly. A total of $819 million worth of IPE can avoid 4762 MACE (95% CI: 0-11,707) versus 20,069 (13,379-25,541), when provided as primary versus secondary prevention therapy; P <.001. The number of avoided MACE is sensitive to IPE price. CONCLUSIONS: Prioritizing IPE therapy for patients with an established cardiovascular disease may provide significantly more value for money than primary prevention. (C) 2021 Elsevier Inc. All rights reserved.
引用
收藏
页码:E415 / E419
页数:5
相关论文
共 20 条
[1]   The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction [J].
Ademi, Zanfina ;
Ofori-Asenso, Richard ;
Zomer, Ella ;
Owen, Alice ;
Liew, Danny .
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2021, 28 (08) :897-904
[2]   Confidence intervals for the number needed to treat [J].
Altman, DG .
BRITISH MEDICAL JOURNAL, 1998, 317 (7168) :1309-1312
[3]  
Amer Diabet Assoc, 2020, DIABETES CARE, V43, pS111, DOI [10.2337/dc20-s010, 10.2337/dc20-S010]
[4]  
[Anonymous], NAT AV DRUG ACQ COST
[5]   Absolute risks rather than incidence rates should be used to estimate the number needed to treat from time-to-event data [J].
Bender, Ralf ;
Kromp, Mandy ;
Kiefer, Corinna ;
Sturtz, Sibylle .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2013, 66 (09) :1038-1044
[6]   Effects of Icosapent Ethyl on Total Ischemic Events From REDUCE-IT [J].
Bhatt, Deepak L. ;
Steg, Ph Gabriel ;
Miller, Michael ;
Brinton, Eliot A. ;
Jacobson, Terry A. ;
Ketchum, Steven B. ;
Doyle, Ralph T. ;
Juliano, Rebecca A. ;
Jiao, Lixia ;
Granowitz, Craig ;
Tardif, Jean-Claude ;
Gregson, John ;
Pocock, Stuart J. ;
Ballantyne, Christie M. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (22) :2791-2802
[7]   Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia [J].
Bhatt, Deepak L. ;
Steg, P. Gabriel ;
Miller, Michael ;
Brinton, Eliot A. ;
Jacobson, Terry A. ;
Ketchum, Steven B. ;
Doyle, Ralph T., Jr. ;
Juliano, Rebecca A. ;
Jiao, Lixia ;
Granowitz, Craig ;
Tardif, Jean-Claude ;
Ballantyne, Christie M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (01) :11-22
[8]   The economic burden of hypertriglyceridemia among US adults with diabetes or atherosclerotic cardiovascular disease on statin therapy [J].
Case, Brian C. ;
Bress, Adam P. ;
Kolm, Paul ;
Philip, Sephy ;
Herrick, Jennifer S. ;
Granowitz, Craig B. ;
Toth, Peter P. ;
Fan, Wenjun ;
Wong, Nathan D. ;
Hull, Michael ;
Weintraub, William S. .
JOURNAL OF CLINICAL LIPIDOLOGY, 2019, 13 (05) :754-761
[9]  
FDA Endocrinologic and Metabolic Drugs Advisory Subcommittee, AMR101 FDA END MET D
[10]   The cost-effectiveness of omega-3 polyunsaturated fatty acids - The Australian healthcare perspective [J].
Gao, Lan ;
Moodie, Marj ;
Li, Shu-Chuen .
EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2019, 67 :70-76